Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in
infants and young children, with favorable safety and immunogenicity profiles. These …

In contrast to earlier pneumococcal vaccines, conjugate vaccines hold promise for reducing
pneumococcal morbidity and mortality in infants and young children. The first commercially …

Since 2000, when the first pneumococcal conjugate vaccine was introduced into routine use
in the USA, it has had a substantial impact on invasive pneumococcal disease both in the …

Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and
acute otitis media in children and adults worldwide. In the age group of< 2 years the …

A 7-valent pneumococcal conjugate vaccine has demonstrated an impact on pneumococcal
bacteremia in the immunized pediatric population, extending to nonimmunized adults via …

This book describes the development of protein conjugate vaccines against pneumococcal
disease, their impact on respiratory and other pneumococcal infections, and the vaccines' …

Streptococcus pneumoniae-related infections have a major global impact on healthcare,
especially in the developing world, and are considered the number one vaccine-preventable …

To assess whether certain serogroups of Streptococcus pneumoniae are preferentially
associated with specific disease manifestations, we analyzed all recent pneumococcal …

Efficacy of pneumococcal conjugate vaccines in large scale f... : The Pediatric Infectious Disease
Journal Efficacy of pneumococcal conjugate vaccines in large scale field trials : The Pediatric …

The universal immunization of infants and toddlers with pneumococcal conjugate vaccine
(PCV) in the United States beginning in 2000 heralded a new era for pneumococcal disease …